BRCA1 and serous adenocarcinoma: A patient with a serous carcinoma harboring a BRCA1 mutation was treated with niraparib after the progression of the disease with whole-brain radiotherapy (WBRT) plus temozolomide, achieving survival of 13 months from the onset of BMs [102].